)

Novartis (NOVN) investor relations material
Novartis Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Achieved double-digit sales growth and core margin expansion in Q2 2025, leading to an upgrade in full-year bottom-line guidance.
Key launches such as Kisqali, Semblix, and Pluvicto accelerated, with robust execution across the portfolio and pipeline milestones reached.
Net sales rose to $14.1B in Q2, driven by strong US growth and key brands, partially offset by generic competition.
Announced CFO transition: Harry Kirsch to retire in 2026, Mukul Mehta named successor.
Focus remains on four core therapeutic areas and continued investment in emerging technology platforms and priority geographies.
Financial highlights
Q2 net sales grew 11–12% year-over-year to $14.1B; H1 net sales reached $27.3B, up 12–13%.
Core operating income up 21% in Q2 to $5.9B; core margin reached 42.2%, a 340 bps improvement.
Core EPS $2.42 in Q2, up 24%; H1 core EPS $4.69, up 27%.
Free cash flow for Q2 was $6.3B, up 37%; H1 free cash flow $9.7B–$10B, up 46%.
Net income increased 24–26% in Q2 to $4.0B.
Outlook and guidance
Upgraded full-year 2025 bottom line guidance: core operating income now expected to grow in the low teens (13–14%).
High single-digit sales growth expected for the full year.
Guidance assumes US Entresto generic entry mid-2025; each month of US Entresto sales worth $400M.
Core tax rate expected at 16–16.5%.
Q4 2025 growth expected to be impacted by prior-year one-time items and potential US generics impact.
Next Novartis earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Swiss Pharmaceuticals
Novartis International AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland. Established in 1996 through the merger of two companies, Novartis has cemented its place as one of the world's largest and most influential pharmaceutical companies with operations in over 150 countries. The company's portfolio includes a range of medicines, generic drugs, eye care devices, and consumer health products.
Roots in Swiss Pharmaceutical Companies
Novartis can trace its roots in two Swiss chemical companies, Ciba-Geigy and Sandoz, which had both been active in the global pharmaceutical industry for over a century before their merger. The fusion in 1996 aimed to leverage their combined strength in research and development, resulting in a global pharmaceutical behemoth. Novartis has since consistently ranked among the largest healthcare companies globally, partly due to its strong commitment to the development of new treatments.
A Diversified Pharmaceutical Powerhouse
Novartis operates under three main divisions: Innovative Medicines, Sandoz (generics), and Alcon (eye care). The Innovative Medicines division also referred to as the pharmaceuticals division, is dedicated to developing, manufacturing, and marketing patented prescription drugs. It includes two business units: Novartis Oncology and Novartis Pharmaceuticals, which target various therapeutic areas, including oncology, cardiology, respiratory, neuroscience, and ophthalmology, to name a few. Sandoz, the generics division of Novartis, provides high-quality, affordable medicines that treat some of the most prevalent healthcare issues. Lastly, the Alcon division focuses on eye care, manufacturing medical devices and products for eye care professionals and patients. They operate in the same field as companies such as Roche, Sanofi, Pfizer, and other large pharmaceutical companies.
Keeping Up With the Times
While remaining at the forefront of pharmaceutical innovation, Novartis continuously aims to refine its product portfolio and adapt to the ever-evolving healthcare landscape. The company has made significant strides in gene and cell therapies, most notably with Kymriah, a CAR-T cell therapy for certain types of blood cancers. Moreover, Novartis is working in digital health, employing data science and digital technologies to aid in drug discovery, patient care, and even the way clinical trials are conducted. The goal is to make treatments more personalized and more efficient, further enhancing patient outcomes.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage